Drug combo aims to shrink Hard-to-Treat sarcomas
NCT ID NCT04025931
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of two drugs—chidamide and toripalimab—in people with advanced soft-tissue sarcoma that has not responded to standard treatments. Chidamide is a pill that may help the immune system recognize cancer cells, while toripalimab is an immunotherapy given by IV. The study aims to see if this combination can shrink tumors or slow disease progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chidamide and toripalimab
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced soft-tissue sarcoma who have run out of standard therapies.
What could go wrong
This is a relatively small, early-phase trial, so the results may not apply to all sarcoma types. The combination may cause side effects and may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen Univerisity
Guangzhou, Guangdong, 510000, China